SLC25A30 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:253512, HGNC:27371, KMCP1, MIM:610793, NM_001010875, NM_001286806, NM_001286807, NP_001010875, NP_001273735, NP_001273736, SLC25A30, XM_005266321, XM_005266322, XM_006719793, XM_006719794, XM_011535026, XM_011535027, XM_017020523, XM_017020524, XP_005266378, XP_005266379, XP_006719856, XP_006719857, XP_011533328, XP_011533329, XP_016876012, XP_016876013, solute carrier family 25 member 30

Id:ENSG00000174032

Entrez:253512

Ensembl:ENSG00000174032

Description:solute carrier family 25 member 30

Although the outer mitochondrial membrane is permeable to many small metabolites, transport of solutes across the inner mitochondrial membrane is achieved by members of the mitochondrial carrier protein family, such as SLC25A30 (Haguenauer et al., 2005 [PubMed 15809292]).[supplied by OMIM, Mar 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View SLC25A30's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with SLC25A30.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using SLC25A30.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for SLC25A30.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with SLC25A30.

Results found

Linked to

	Label	Description
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 5 PACLITAXEL HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE125211 0 V 1 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 0 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE184210 0 V 1 GLUCAGON MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE130401 4 V 3 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE182150 KIT LSD1 MYC inhibition 6 v 8 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE230634 PARP inhibition 0 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE210655 1 V 0 CISPLATIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE95688 7 V 2 GLUTATHIONE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE172016 2 V 5 PACLITAXEL HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE125211 0 V 1 NICOTINAMIDE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE172016 2 V 0 PACLITAXEL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE184210 0 V 1 GLUCAGON MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE130401 4 V 3 TRAMETINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE182150 KIT LSD1 MYC inhibition 6 v 8 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE230634 PARP inhibition 0 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE210655 1 V 0 CISPLATIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE95688 7 V 2 GLUTATHIONE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.